Finance

Lists
T1EV34:BVMF
Teva Pharmaceutical Industries Bdr
98,10 R$
0,00%
(0,00) 1D
7 հոկ, 13:35:03 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for T1EV34...
Mkt. cap
47,04 մլրդ
Avg. vol.
127,00
Volume
0,00
52-wk high
101,90 R$
52-wk low
51,60 R$
Shares outstanding
1,17 մլրդ
No. of employees
32 հզր
Mkt. cap
47,04 մլրդ
Avg. vol.
127,00
Volume
0,00
52-wk high
101,90 R$
52-wk low
51,60 R$
Shares outstanding
1,17 մլրդ
No. of employees
32 հզր
News stories
From web sources and news partners
Profile
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
About Teva Pharmaceutical Industries Bdr
CEORichard Francis
Employees32 հզր
Founded13 փտվ, 1944 թ.
Headquarters-
Sector-
Websiteteva.co.il
Last report
29 հլս, 2026 թ.
Fiscal period
Q2 2026
0,02 $ / 0,11 $
-81,46%miss
Revenue / Est. (USD)
4,14 մլրդ / 4,03 մլրդ
+2,79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
4,48 մլրդ
4,71 մլրդ
3,98 մլրդ
4,14 մլրդ
Cost of goods sold
2,18 մլրդ
2,06 մլրդ
2,01 մլրդ
1,99 մլրդ
Cost of revenue
2,18 մլրդ
2,06 մլրդ
2,01 մլրդ
1,99 մլրդ
Research and development expenses
256,00 մլն
267,00 մլն
222,00 մլն
970,00 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
973,00 մլն
1,12 մլրդ
1,00 մլրդ
1,03 մլրդ
Operating expense
1,24 մլրդ
1,37 մլրդ
1,21 մլրդ
1,99 մլրդ
Total operating expenses
3,41 մլրդ
3,43 մլրդ
3,22 մլրդ
3,98 մլրդ
Operating income
1,07 մլրդ
1,28 մլրդ
763,00 մլն
167,00 մլն
Other non operating income
-27,00 մլն
-
-13,00 մլն
-69,00 մլն
EBT including unusual items
648,00 մլն
90,00 մլն
436,00 մլն
-455,00 մլն
EBT excluding unusual items
832,00 մլն
1,08 մլրդ
547,00 մլն
-57,00 մլն
Income tax expense
214,00 մլն
-390,00 մլն
67,00 մլն
121,00 մլն
Effective tax rate
33,02%
-433,33%
15,37%
-26,59%
Other operating expenses
9,00 մլն
-17,00 մլն
-14,00 մլն
-18,00 մլն
Net income
433,00 մլն
480,00 մլն
369,00 մլն
-576,00 մլն
Net profit margin
9,67%
10,19%
9,27%
-13,91%
Earnings per share
0,78
0,96
0,53
0,02
Interest and investment income
-
92,00 մլն
-
-
Interest expense
-205,00 մլն
-280,00 մլն
-191,00 մլն
-186,00 մլն
Net interest expenses
-205,00 մլն
-188,00 մլն
-191,00 մլն
-186,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
1,32 մլրդ
1,54 մլրդ
1,00 մլրդ
408,00 մլն
Gain or loss from assets sale
-
-
-8,00 մլն
-12,00 մլն
AI content may include mistakes. Learn more
Google Apps